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Abstract
Introduction: Gene expression profiling is rapidly becoming a useful and informative tool in a much needed area
of research. Identifying patients as to whether they will respond or not to a given treatment before prescription is
not only essential to optimise treatment outcome but also to lessen the economic burden that such drugs can
have on healthcare resources. In rheumatoid arthritis (RA), there is of yet no genetic/genomic biomarker which can
accurately predict response to TNF inhibitor biologics prior to treatment, despite much interest in this area. Multiple
studies have reported findings on potential candidate genes; however, due to relatively small sample sizes or lack
of sufficient validation, results have been disappointingly inconsistent. The aim of this research was to further
explore the predictive value of a previously reported association between CD11c expression and response to the
TNF inhibitor biologics, adalimumab and etanercept.
Methods: Real-time qPCR was performed using whole blood RNA samples obtained from seventy-five rheumatoid
arthritis patients about to commence treatment with a TNF inhibitor biologic drug, whose response status was
determined at 3-month follow-up using the EULAR classification criteria. Relative quantification of CD11c using
the comparative CT method outputted differential expression between good-responders and non-responders
as a fold-change.
Results: Relative expression of CD11c in patients receiving TNF inhibitor biologics yielded a decrease of 1.025
fold in good-responders as compared to non-responders (p-value = 0.36). Upon stratification of patients dependent upon
the specific drug administered, adalimumab or etanercept, similar findings to the full cohort were observed, decreases of
1.015 (p-value = 0.33) and 1.032 fold (p-value = 0.13) in good-responders compared to non-responders, respectively.
Conclusion: The results from this study reveal that CD11c expression does not correlate with response to TNF inhibitor
biologics when tested for within pre-treatment whole blood samples of rheumatoid arthritis patients.
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Introduction
Rheumatoid arthritis (RA) is a systemic autoimmune
disorder of unknown aetiology affecting around 400,000
adults in the UK [1] and is characterised by chronic in-
flammation, joint swelling and fatigue. Early diagnosis
and aggressive treatment are known to correlate with
improved long-term outcome, ultimately resulting in a
better quality of life [2–5]. Within the last decade, the
treatment strategy for RA has progressed considerably,
particularly since the introduction of biologic therapies,
which greatly benefit patients who do not respond to
traditional disease-modifying anti-rheumatic drugs
(DMARDs) [6]. Although effective, biologic agents are
costly (approximately £10,000 per patient per year) and
are reserved in many countries for those patients with
moderate to severe RA, who have previously failed to re-
spond to more than one DMARD, including methotrex-
ate (MTX) [1]. However, up to 40 % of RA patients
receiving biologic agents fail to respond satisfactorily.
Clinical characteristics such as age, gender and con-
current DMARD use only contribute 15–17 % of the
variance observed in treatment response [7]. Hence,
identifying predictive biomarkers to help clinicians select
an effective drug early in the disease course has been
highlighted as a research priority. In the field of oncol-
ogy, transcriptional profiling is routinely utilized to strat-
ify treatment regimens; for example, over-expression of
the HER2/neu gene in breast cancer patients is used to
inform the prescription of trastuzumab (Herceptin),
whilst oestrogen receptor expression is associated with a
better response to tamoxifen [8–10]. It is possible, there-
fore, that expression biomarkers of response could be
identified in other fields of medicine. Indeed, expression
of CD11c (ITGAX), an integrin molecule involved in cell
adhesion and chemotaxis [11] has shown evidence for
association with response to treatment with a TNF in-
hibitor drug (TNFi) in RA patients. It was reported that
increased expression of CD11c prior to treatment signifi-
cantly correlates with good response to adalimumab
monotherapy (p value <0.0001); with sensitivity of 100 %
and specificity of 91.7 % [12].
However, the previously observed association was con-
ducted using RA monocytes and due to the impractical-
ity of using such a sample source in clinical settings, it is
likely to hamper the adoption of this biomarker for rou-
tine clinical use. Ideally, for a predictive biomarker to be
useful in a clinical setting, it should be possible to test
the biomarker in a biological sample that is readily avail-
able, acquired through a minimally invasive procedure
(resulting in the least possible distress to the patient)
and requiring minimal processing following collection.
Hence, whole blood would be an ideal source for a bio-
marker. We therefore set out with the aim not to repli-
cate the previously reported observation, but to (1)
establish whether expression of CD11c is detectable in
whole blood samples collected from RA patients about
to commence treatment with a TNFi biologic drug and
(2) correlate pre-treatment whole blood expression levels
with response to TNFi biologic drugs both as a whole
and sub-grouped by the drug received (both adalimumab
and etanercept were tested).
Methods
Patients
Seventy-five patients with RA were selected for analysis
from the Biologics in Rheumatoid Arthritis Genetics and
Genomics Syndicate (BRAGGSS), which recruits pa-
tients from over 50 contributing centres across the UK,
who are about to commence treatment with biologic
drugs for the first time, as described in detail previously
[7]. Inclusion criteria were as follows: participants were
Caucasian, over the age of 18 years, fulfilled the 1987
American College of Rheumatology (ACR) criteria for
RA and gave written informed consent. Upon recruit-
ment, patients were asked to provide blood samples for
the collection of laboratory and serological data and pro-
vide psychological and clinical information. As part of
the study, patients are prospectively followed for 12
months and provide further samples/information at
months 3, 6 and 12. As such, the 28-joint count disease
activity score (DAS28) using four variables (the number
of tender and swollen joints, erythrocyte sedimentation
rate (ESR)/C-reactive protein (CRP) and patient global
assessment score) could be recorded prior to and at 3, 6
and 12 months [13]. The BRAGGSS study was approved
by NRES Committee North West - Greater Manchester
South (REC Ref: 04/Q1403/37).
For this study, patients were selected if they were about
to commence treatment with the TNFi biologic drugs, ada-
limumab or etanercept, and if they showed either a good
response or no response to therapy at 3-month follow up.
Clinical efficacy of the TNFi biologic drug was assessed at
3-month follow-up using the established European League
Against Rheumatism (EULAR) classification criteria. Good-
responder patients were defined by having a DAS28 ≤ 3.2
but also having decreased from the pre-treatment DAS28
by >1.2. A non-responder was defined as having a DAS28
score that did not decrease by >0.6 or was between 0.6–1.2
but also with an end score >5.1. Moderate responders were
excluded from this study.
Blood collection
Pre-treatment whole blood samples were collected into
either Tempus ™ Blood RNA Tubes (3 ml) (Applied Bio-
systems, Foster City, CA, USA) or PAXgene Blood RNA
collection tubes (2.5 ml) (Qiagen, Valencia, CA, USA).
Following collection, samples were shipped to the cen-
tral processing laboratory at the Arthritis Research UK
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Centre for Genetics and Genomics (ARUK-CoGG)
where they were logged onto the laboratory information
management system (LIMS) and stored in an allocated
freezer location at –80 °C until RNA extraction.
RNA extraction
RNA extraction kits were used to extract total RNA
from whole blood samples following the manufac-
turer’s instructions: i.e., Tempus™ Spin RNA Isolation
Kit (Applied Biosystems, Foster City, CA, USA) and
PAXgene RNA Isolation Kit (Qiagen, Valencia, CA,
USA). In both cases an on-column DNase digestion
step was performed to remove any potential genomic
DNA contamination. Quantification was performed
using the Nanodrop ND-1000 (Thermo Scientific,
Waltham, MA, USA) and assessment of RNA integrity
was assessed using the 2100 Bioanalyzer (Agilent,
Santa Clara, CA, USA). Total RNA with 260/280 and
260/230 ratios in the range of 1.8–2.2 and RNA integ-
rity number (RIN) >5 were taken forward for analysis.
cDNA Synthesis and RT-qPCR
Total RNA was reverse transcribed into high-quality sin-
gle stranded cDNA using the High Capacity cDNA Re-
verse Transcription Kit (Applied Biosystems, Foster City,
CA, USA) following the manufacturer’s instructions.
Briefly, 10 μl total RNA was reverse transcribed in a 10-
μl master-mix solution containing MultiScribe™ Reverse
Transcriptase and placed in a thermal cycler pro-
grammed according to the manufacturer’s instructions.
Quantitative real-time PCR (RT-qPCR) was performed
using the QuantStudio™ 12 K Flex real-time qPCR system
(Applied Biosystems, Foster City, CA, USA) which em-
ploys TaqMan based technology. Relative expression levels
of CD11c were determined by normalising CD11c mRNA
transcripts against GAPDH and ACTB mRNA transcripts
(housekeeping genes (HKGs)). All TaqMan® gene expres-
sion assays used were assays-by-demand supplied by
Applied Biosystems: ACTB Hs99999903_m1, GAPDH
Hs99999905_m1 and ITGAX (CD11c) Hs00174217_m1.
All experiments were performed in triplicate, under PCR
amplification conditions in accordance with the manufac-
turer’s instructions.
Statistical analysis
All statistical analysis was performed using the data ana-
lysis and statistical software programme STATA/SE 11.2
(StataCorp LP, College Station, TX, USA) [14]. The com-
parative cycle threshold (CT) method was used to rela-
tively quantify CD11c expression against an average of
the HKGs resulting in CD11c expression being pre-
sented as a fold-change in good responders as compared
to non-responders [15]. Subsequently, normalised
CD11c expression values were used in a logistic
regression model; both univariate and multivariate
models were tested (the multivariate model including
baseline characteristics with a p value <0.05 for compari-
son between the response phenotypes as covariates).
The analysis was performed in two stages. First, the ana-
lysis was performed on the full cohort and second, the
analysis was repeated following stratification of patients
into sub-groups based on the TNFi biologic drugs they
received.
Results
Seventy-five patients receiving TNFi biological therapy
were included in this study. The summarised cohort
characteristics of these patients can be seen in Table 1
and are typical of patients with active and severe disease.
Similar baseline characteristics were observed for good
responders and non-responders except that good re-
sponders were slightly younger (p value = 0.023) and pre-
sented with a lower health assessment questionnaire
(HAQ) score (p value = 0.026). Using the EULAR classi-
fication criteria, 41 patients were classified as TNFi re-
sponders and 34 patients as TNFi non-responders at 3
months following commencement of treatment
(Table 1).
Good-responder and non-responder patients receiving
TNFi biologic drugs demonstrated similar baseline
CD11c expression profiles when normalised against the
average HKGs profile using the comparative CT method
(see Fig. 1), equating to a 1.025-fold decrease in good
responders as compared to non-responders (multivari-
ate p value = 0.36; using age at baseline and baseline
HAQ score as covariates).
As the previously reported association was reported in
patients receiving adalimumab, the analysis was repeated
after stratifying patients based on the type of treatment
received; this equated to 25 adalimumab patients (16 good
responders and 9 non-responders) and 50 etanercept
patients (25 good responders and 25 non-responders).
Stratified cohort characteristics are listed in Table 1. No sig-
nificant associations were observed in the stratified analysis.
Adalimumab patients yielded a 1.015-fold decrease in
good-responders as compared to non-responders (multi-
variate p value = 0.33, using concurrent DMARD use as a
covariate) and etanercept patients yielded a 1.032-fold de-
crease in good-responders as compared to non-responders
(multivariate p value = 0.13, using baseline HAQ score as a
covariate).
The previous studies initial exploratory analysis of
seven RA patients treated with adalimumab showed that
higher CD11c expression correlated with good response.
However further analysis revealed that the association
was only observed in patients receiving monotherapy
and was not observed in adalimumab-treated RA pa-
tients when adalimumab was prescribed with MTX, as is
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common in clinical practice. Further analysis restricted
to patients on monotherapy was undertaken in the
current study where possible; however, this did not lead
to any significant findings at the 5 % significance thresh-
old, though the small group numbers (n = 7) included in
the analysis limited the conclusions that could be drawn.
Discussion
This study has employed a candidate gene approach
to further explore the potential predictive capability
of expression of a previously reported treatment
response gene, CD11c, using a clinically applicable
sample source (as opposed to the original sample
source of monocytes). To achieve this, expression of
CD11c was measured in whole blood samples col-
lected at baseline from RA patients about to undergo
treatment with TNFi biologic drugs. However, no evi-
dence for association was detected for TNFi drug
therapy as a class or after sub-grouping by specific
TNFi agents.
A strength of this study was the large sample size
tested relative to previous treatment response gene ex-
pression profiling studies and the use of samples from
extreme ends of the response spectrum, which resulted
in greater power to detect the same effect size as previ-
ously reported in the study of adalimumab-treated
patients [12]. For example, in the original study, after
initial identification of CD11c expression associating
with treatment response in 7 patients by microarray ana-
lysis, validation was conducted in 27 patients from an
independent cohort by RT-PCR [12]. By contrast, the
current study of 75 RA samples is, to the best of our
knowledge, one of the largest and most well-powered
treatment response studies of gene expression conducted
to date in RA.
A major difference between this study and the original
study was the testing of CD11c expression within whole
blood rather than in monocytes; therefore, as previously
stated, the previous association has not been faithfully
tested. The discovery of the correlation between CD11c
expression and adalimumab response may be wholly
cell-type-specific and due to the heterogeneous nature of
whole blood any signal could be confounded by satur-
ation from other cells. However, a recent study [16]
demonstrated that CD11c expression is quantifiable in
whole blood and we therefore elected to test whole
blood, as this sample type would be most readily trans-
lated to clinical benefit, whereas isolation of specific cell
populations is currently impractical in a clinical setting.
Further experiments in an enriched monocyte cell popu-
lation and whole blood samples will be needed to ex-
plore this further.
Table 1 Summarised cohort/stratified baseline characteristics of patients receiving biologic drugs, analysed for CD11c expression by
qPCR
Full cohort (n = 75) Etanercept (n = 50) Adalimumab (n = 25)
Cohort
characteristics
NR (n = 34) R (n = 41) P value NR (n = 25) R (n = 25) P value NR (n = 9) R (n = 16) P value
Gender, female,
n (%)
27 (79.4 %) 31 (75.6 %) 0.695a 20 (80 %) 20 (80 %) 1.00a 7 (77.8 %) 11 (68.8 %) 0.629a
Age, baseline,
years, mean (SD)
59.3 (12.3) 53.3 (10.3) 0.023b 61.2 (12.2) 54.86 (11.4) 0.065b 54.3 (11.7) 50.7 (8.2) 0.258b
Concurrent
DMARDs, n (%)
28 (82.4 %) 36 (90 %) 0.338a 22 (88 %) 21 (84 %) 0.684a 6 (66.7 %) 15 (100 %) 0.017a
Baseline DAS28,
median (IQR)
6.2 (5.4–6.6) 5.8 (5.5–6.3) 0.131c 6.2 (5.8–6.6) 5.9 (5.5–6.2) 0.156c 6.6 (5.6–7.03) 5.6 (5.3–6) 0.101c
3 month DAS28,
median (IQR)
5.65 (5.4–6.2) 2.15 (1.6–2.5) <0.001c 5.6 (5.3–5.9) 2.3 (1.9–3) <0.001c 6.6 (5.3–6.8) 1.95 (1.6–2.2) <0.001c
Baseline TJC,
median (IQR)
16 (10–19) 13 (10–16) 0.205c 14 (10–18) 13 (10–15) 0.515c 18 (16–24) 13 (10–19) 0.157c
Baseline SJC,
median (IQR)
8.5 (4–13) 9 (6–13) 0.701c 7 (4–11) 9 (6–13) 0.268c 11 (9–15) 8.5 (6–13) 0.211c
Baseline ESR,
median (IQR), n
33 (14–44), 26 18 (14–33), 35 0.11c 32 (23–41), 21 18 (10–34), 23 0.158c 34 (10–60), 5 20.5 (14–31), 12 0.712c
Baseline HAQ,
median (IQR), n
2.06 (1.38–2.3), 22 1.5 (1.13–2), 32 0.026c 2.1 (1.9–2.3), 17 1.4 (1.1–1.6), 19 0.006c 1.9 (1.3–2.1), 5 1.8 (1.1–2.4), 13 0.96c
Tempus™ Blood
Tube, n (%)
21 (61.8 %) 22 (53.4 %) 0.48a 15 (60 %) 14 (56 %) 0.774a 6 (66.67 %) 8 (50 %) 0.420a
aCalculated using chi-square test. bCalculated using two independent samples t test. cCalculated using Wilcoxon-Mann–Whitney test. Samples were grouped
according to treatment response. NR non-responders, R responders, DAS28 disease activity score in 28 joints, SJC swollen joint count, TJC tender joint count,
ESR erythrocyte sedimentation rate, HAQ health assessment questionnaire
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Another reason for the lack of association could be
due to the use of the EULAR classification criteria to de-
fine response to treatment within this study, whereas in
the original study patients were classified according to
the ACR response criteria. Both outcome measures are
well-validated and therefore commonly used to assess
response to treatment; however, there is debate as to the
concordance between them, with the use of which meas-
ure being at the discretion of the researcher. For ex-
ample, one study reported that the concordance
between classifying an ACR20 and EULAR response was
high (with all 94 ACR20 patients found in the EULAR
response group), however, in contrast, concordance be-
tween the ACR50 and EULAR response groups was poor
(with only 34 ACR50 patients (out of 53) found within
the EULAR group) [17]. Of note, ACR scores could not
be calculated within the current study.
Another consideration to take into account is that dif-
ferent TaqMan® primers were used within this study,
compared to the original. However, both primer sets de-
tected the same transcript so this is not the reason for
the lack of replication. Furthermore, it could be that the
association between CD11c expression and response is
only applicable to patients receiving adalimumab mono-
therapy, as the signal was lost upon administration of
concomitant MTX. However, according to the National
Institute for Health and Care Excellence (NICE) guide-
lines for the treatment of patients with RA in the UK,
biologic drugs should be given in conjunction with MTX
and only in patients who have proven intolerant or de-
veloped an adverse reaction should a biologic be given
as monotherapy [18]. This would therefore limit the use-
fulness of CD11c as a treatment response biomarker, as
those receiving adalimumab monotherapy will only rep-
resent a small minority of the overall number of patients
receiving biologic drugs.
Given the success of gene expression profiling in guid-
ing therapy decisions in the field of oncology, expression
profiling is currently being explored as a biomarker pre-
dictive of treatment response to other therapies, includ-
ing biologic treatments used for RA [19–23]. However,
results so far have been disappointing as inconsistencies
in the reported findings have been observed. This is due
to a number of reasons, including differences in study
design (type of tissue used, treatment/dose received,
classification criteria applied or the platform used to
generate the results) or lack of statistical power. Future
well-powered studies of treatment response are therefore
needed in RA and whole blood remains an attractive tis-
sue to test for biomarkers in the clinical setting. Consid-
ering this, it would be ideal to agree upon a standardised
method of generating data in treatment response studies
before a clinical biomarker can be identified and suffi-
ciently validated for use in the clinic.
Conclusion
We hypothesised that the expression profile of CD11c,
previously reported to be associated with response to
adalimumab therapy when tested in monocytes, would
Fig. 1 Relative CD11c expression stratified by response phenotype.
Pre-treatment CD11c expression normalised to the average
housekeeping gene (HKG) profile and grouped according to
treatment response (presented as 2-ΔCt). Measured in 75 total RNA
samples from patients about to receive anti-TNF treatment (a), in 50
total RNA samples from patients about to receive the anti-TNF
etanercept (b) and in 25 total RNA samples from patients about to
receive the anti-TNF adalimumab (c)
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also correlate with response to TNFi agents with enough
discriminatory power to be detectable in whole blood
samples. However, our study shows that expression of
CD11c in baseline whole blood samples does not correl-
ate with treatment outcome in etanercept-treated or
adalimumab-treated RA patients.
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